PURE Bioscience (OTCMKTS:PURE – Get Free Report) was the recipient of a large drop in short interest in October. As of October 15th, there was short interest totaling 4,381 shares, a drop of 77.3% from the September 30th total of 19,268 shares. Based on an average daily volume of 65,650 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.
PURE Bioscience Stock Performance
Shares of PURE opened at $0.07 on Thursday. The company has a market cap of $9.50 million, a price-to-earnings ratio of -2.44 and a beta of 0.33. The stock has a fifty day moving average price of $0.07 and a two-hundred day moving average price of $0.07. PURE Bioscience has a 52-week low of $0.04 and a 52-week high of $0.10.
About PURE Bioscience
PURE Bioscience, Inc develops and commercializes antimicrobial products based on its proprietary silver dihydrogen citrate (SDC) technology. SDC is designed to provide broad-spectrum antimicrobial activity and is used as an active ingredient in formulations intended for applications such as surface disinfection, sanitation and odor control.
The company’s product portfolio has included PureGreen24, a disinfectant and sanitizer marketed for use on hard, nonporous surfaces in commercial, institutional, industrial and residential settings.
Further Reading
- Five stocks we like better than PURE Bioscience
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
